カテゴリー： 世界, 医療/バイオ, Grand View Research

世界の多形膠芽腫治療市場2023-2030：治療別（放射線療法、免疫療法）、薬剤クラス別、エンドユーザー別、地域別

【英語タイトル】Glioblastoma Multiforme Treatment Market Size, Share & Trends Analysis Report By Treatment (Radiation Therapy, Immunotherapy), By Drug Class, By End-use, By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料（GRV23NOV127）・商品コード：GRV23NOV127
・発行会社（調査会社）：Grand View Research
・発行日：2023年9月
・ページ数：110
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥880,600見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,028,600見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,324,600見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

多形膠芽腫治療市場の成長と動向
Grand View Research社の最新レポートによると、世界の多形膠芽腫治療市場規模は2030年までに51億米ドルに達する見込みです。2023年から2030年までのCAGRは9.7%で拡大する見込みです。この市場を牽引しているのは、有病率の上昇と、新規療法や併用療法に対する承認の増加です。

近年では、革新的な製品の登場や、ガイドラインの好転と罹患率の上昇を背景とした大手製薬企業の市場への関心の高まりにより、業界は急成長を遂げています。例えば、ブBristol Myers Squibb; CNS Pharmaceuticals, Inc.; and Bayerなどは、多形性膠芽腫に対する新製品を開発中です。これらの製品により、今後数年間は市場での競争激化が予想されます。

さらに、企業は新規治療法を開発するために共同研究を行っています。例えば、2019年10月、臨床段階のバイオテクノロジー企業であるAdvaxis, Inc.は、多形性膠芽腫のマウス腫瘍モデルで同社のLmテクノロジーを使用することによる新規免疫療法の開発と商業化のためのカリフォルニア大学との研究協力契約を発表しました。研究者と市場プレイヤーのコラボレーションが増加することで、多形性膠芽腫に対する新規かつ効果的な治療オプションの開発が促進されることが期待されます。

既存企業は、製品ポートフォリオを多様化するために、パイプライン製品を有する新規企業の買収に積極的です。例えば、2019年5月、MerckはPeloton Therapeuticsの11億米ドルの先行買収を発表し、これにより試験中の膠芽腫治療薬PT2977へのアクセスが可能になりました。この買収により、パイプラインが強化され、将来の収益創出能力が向上すると思われます。

多形性膠芽腫に罹患している人々を教育し、研究開発活動や治療のための資金を調達することで認知度を高めるために、世界中の政府や非政府機関が行っているさまざまな取り組みが、予測期間中の多形性膠芽腫（GBM）治療市場の成長を促進すると期待されています。例えば、モバイル・メッセージング・プラットフォームのPing Mobile社は、脳腫瘍に関する認識を高めるためのモバイル・キャンペーンを開始しました。これは、多形性膠芽腫に関する認知度を高め、多形性膠芽腫の研究活動への寄付を動機付けるのに役立ちます。

National Brain Tumor Society（全米脳腫瘍協会）、Brain Tumour Foundation of Canada（カナダ脳腫瘍財団）、Cure Brain Cancer Foundation（キュアブレインキャンサー財団）などの団体も、脳腫瘍に対する人々の意識を高めるために多くの啓発キャンペーンを行っています。英国では、3月を脳腫瘍啓発月間とし、脳腫瘍研究の会員団体によってキャンペーンが実施されています。このキャンペーンの主な目的は、脳腫瘍研究のための資金が不足していることに対する認識を広めることであり、脳腫瘍とその治療に対する人々の理解を助けることです。さらに、Novocureは脳腫瘍啓発月間に、多形膠芽腫についての認識を広めるために様々な活動を行いました。

多形膠芽腫治療市場レポートハイライト

- 治療法別では、2022年には放射線療法が37.0%の売上シェアで市場を席巻、これは生存率の向上によるものです。

- 薬剤クラス別では、その他セグメントが2022年に最大の収益シェアを占めました。このセグメントには、エベロリムス、コルチコステロイド、5-アミノレブリン酸（5-ALA）が含まれます。

- 病院セグメントは、2022年の多形性膠芽腫治療市場において最大の収益シェアを占め、予測期間中もその主導的地位を維持すると予測されています。患者は、治療へのアクセスや利便性の観点から病院を好みます。

- アジア太平洋地域は、テモゾロミドのジェネリック医薬品の市場参入、経済の改善、高齢者人口の増加、医療分野への投資の増加など、さまざまな要因により、予測期間中に11.1%という最も速い成長率を記録する見込みです。

- 2022年には北米が43.4%の最大シェアを占めました。医療セクターの発展に対する政府の支援、希少疾患に対する高い認識、質の高い医療施設への容易なアクセス、有利な償還政策などが、同地域の市場成長の主な要因となっています。

第1章 調査方法・範囲
第2章 エグゼクティブサマリー
第3章 世界の多形膠芽腫治療市場変数・傾向・範囲
第4章 世界の多形膠芽腫治療市場：治療別予測・傾向分析
第5章 世界の多形膠芽腫治療市場：薬剤クラス別予測・傾向分析
第6章 世界の多形膠芽腫治療市場：エンドユーザー別予測・傾向分析
第7章 世界の多形膠芽腫治療市場：地域別予測・傾向分析
第8章 競争状況

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Treatment
1.1.2. Drug class
1.1.3. End Use
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Treatment outlook
2.2.2. Drug class outlook
2.2.3. End-use outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Glioblastoma Multiforme Treatment Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Industry Value Chain Analysis
3.3.1. Reimbursement framework
3.4. Market Dynamics
3.4.1. Market Driver Analysis
3.4.2. Market Restraint Analysis
3.5. Glioblastoma Multiforme Treatment Market Analysis Tools
3.5.1. Industry Analysis – Porter’s Five Forces
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic Landscape
Chapter 4. Glioblastoma Multiforme Treatment Market: Treatment Estimates & Trend Analysis
4.1. Glioblastoma Multiforme Treatment Market: Key Takeaways
4.2. Glioblastoma Multiforme Treatment Market: Treatment Movement & Market Share Analysis, 2022 & 2030
4.3. Surgery
4.3.1. Surgery market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Radiation Therapy
4.4.1. Radiation therapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Chemotherapy
4.5.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Targeted Therapy
4.6.1. Targeted Therapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.7. Tumor Treating Field (TTF) Therapy
4.7.1. Tumor treating field (TTF) therapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.8. Immunotherapy
4.8.1. Immunotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Glioblastoma Multiforme Treatment Market: Drug Class Estimates & Trend Analysis
5.1. Glioblastoma Multiforme Treatment Market: Key Takeaways
5.2. Glioblastoma Multiforme Treatment Market: Drug Class Movement & Market Share Analysis, 2022 & 2030
5.3. Temozolomide
5.3.1. Temozolomide market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Bevacizumab
5.4.1. Bevacizumab market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Lomustine
5.5.1. Lomustine market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Carmustine Wafers
5.6.1. Carmustine Wafers market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Others
5.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Glioblastoma Multiforme Treatment Market: End Use Estimates & Trend Analysis
6.1. Glioblastoma Multiforme Treatment Market: Key Takeaways
6.2. Glioblastoma Multiforme Treatment Market: End-use Movement & Market Share Analysis, 2022 & 2030
6.3. Hospitals
6.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
6.4. Clinics
6.4.1. Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Ambulatory Surgical Centers
6.5.1. Ambulatory Surgical Centers market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Glioblastoma Multiforme Treatment Market: Regional Estimates & Trend Analysis
7.1. Regional Outlook
7.2. Glioblastoma Multiforme Treatment Market by Region: Key Takeaway
7.3. North America
7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.3.2. U.S.
7.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.3.3. Canada
7.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.2. Germany
7.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.3. France
7.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.4. Italy
7.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.5. Spain
7.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.6. Sweden
7.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.7. Norway
7.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.8. Denmark
7.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.2. China
7.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.3. India
7.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.4. Australia
7.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.5. Thailand
7.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.6. South Korea
7.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.6.2. Mexico
7.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.6.3. Argentina
7.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.7. MEA
7.7.1. Saudi Arabia
7.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.7.2. South Africa
7.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.7.3. UAE
7.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.7.4. Kuwait
7.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Market Participant Categorization
8.2.1. Merck & Co., Inc.
8.2.1.1. Company overview
8.2.1.2. Financial performance
8.2.1.3. Product benchmarking
8.2.1.4. Strategic initiatives
8.2.2. Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
8.2.2.1. Company overview
8.2.2.2. Financial performance
8.2.2.3. Product benchmarking
8.2.2.4. Strategic initiatives
8.2.3. Teva Pharmaceutical Industries Ltd.
8.2.3.1. Company overview
8.2.3.2. Financial performance
8.2.3.3. Product benchmarking
8.2.3.4. Strategic initiatives
8.2.4. Sun Pharmaceutical Industries Ltd.
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Product benchmarking
8.2.4.4. Strategic initiatives
8.2.5. Hoffmann-La Roche Ltd.
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Product benchmarking
8.2.5.4. Strategic initiatives
8.2.6. Pfizer, Inc.
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Product benchmarking
8.2.6.4. Strategic initiatives
8.2.7. Amgen, Inc.
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Product benchmarking
8.2.7.4. Strategic initiatives
8.2.8. Arbor Pharmaceuticals, LLC
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Product benchmarking
8.2.8.4. Strategic initiatives
8.2.9. Amneal Pharmaceuticals
8.2.9.1. Company overview
8.2.9.2. Financial performance
8.2.9.3. Product benchmarking
8.2.9.4. Strategic initiatives
8.2.10. Karyopharm Therapeutics, Inc.
8.2.10.1. Company overview
8.2.10.2. Financial performance
8.2.10.3. Product benchmarking
8.2.10.4. Strategic initiatives

List of Tables

Table 1 List of Abbreviations
Table 2 North America glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 3 North America glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 4 North America glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 5 North America glioblastoma multiforme treatments market, by region, 2018 - 2030 (USD Million)
Table 6 U.S. glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 7 U.S. glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 8 U.S. glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 9 Canada glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 10 Canada glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 11 Canada glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 12 Europe glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 13 Europe glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 14 Europe glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 15 Europe glioblastoma multiforme treatments market, by region, 2018 - 2030 (USD Million)
Table 16 Germany glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 17 Germany glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 18 Germany glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 19 UK glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 20 UK glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 21 UK glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 22 France glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 23 France glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 24 France glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 25 Italy glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 26 Italy glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 27 Italy glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 28 Spain glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 29 Spain glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 30 Spain glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 31 Sweden glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 32 Sweden glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 33 Sweden glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 34 Norway glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 35 Norway glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 36 Norway glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 37 Denmark glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 38 Denmark glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 39 Denmark glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 40 Asia Pacific glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 41 Asia Pacific glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 42 Asia Pacific glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 43 Asia Pacific glioblastoma multiforme treatments market, by region, 2018 - 2030 (USD Million)
Table 44 China glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 45 China glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 46 China glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 47 Japan glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 48 Japan glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 49 Japan glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 50 India glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 51 India glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 52 India glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 53 Thailand glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 54 Thailand glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 55 Thailand glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 56 South Korea glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 57 South Korea glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 58 South Korea glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 59 Australia glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 60 Australia glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 61 Australia glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 62 Latin America glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 63 Latin America glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 64 Latin America glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 65 Latin America glioblastoma multiforme treatments market, by region, 2018 - 2030 (USD Million)
Table 66 Brazil glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 67 Brazil glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 68 Brazil glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 69 Mexico glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 70 Mexico glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 71 Mexico glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 72 Argentina glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 73 Argentina glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 74 Argentina glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 75 Middle East and Africa glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 76 Middle East and Africa glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 77 Middle East and Africa glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 78 Middle East and Africa glioblastoma multiforme treatments market, by region, 2018 - 2030 (USD Million)
Table 79 South Africa glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 80 South Africa glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 81 South Africa glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 85 UAE glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 86 UAE glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 87 UAE glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 88 Kuwait glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 89 Kuwait glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 90 Kuwait glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Glioblastoma multiforme treatments: Market outlook
Fig. 9 Glioblastoma multiforme treatments: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Glioblastoma multiforme treatments market driver impact
Fig. 15 Glioblastoma multiforme treatments market restraint impact
Fig. 16 Glioblastoma multiforme treatments market strategic initiatives analysis
Fig. 17 Glioblastoma multiforme treatments market: Treatment movement analysis
Fig. 18 Glioblastoma multiforme treatments market: Treatment outlook and key takeaways
Fig. 19 Surgery market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Radiation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Targeted therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Tumor treating field (TTF) therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Immunotherapy therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Glioblastoma multiforme treatments market: Drug class movement analysis
Fig. 26 Glioblastoma multiforme treatments market: Drug class outlook and key takeaways
Fig. 27 Temozolomide market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Bevacizumab market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Lomustine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Carmustine wafers market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Glioblastoma multiforme treatments market: End-use movement analysis
Fig. 33 Glioblastoma multiforme treatments market: End-use outlook and key takeaways
Fig. 34 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Clinics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Ambulatory Surgical Centers market estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 37 Global glioblastoma multiforme treatments market: Regional movement analysis
Fig. 38 Global glioblastoma multiforme treatments market: Regional outlook and key takeaways
Fig. 39 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

★調査レポート[世界の多形膠芽腫治療市場2023-2030：治療別（放射線療法、免疫療法）、薬剤クラス別、エンドユーザー別、地域別] (コード：GRV23NOV127)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の多形膠芽腫治療市場2023-2030：治療別（放射線療法、免疫療法）、薬剤クラス別、エンドユーザー別、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の大腸がん治療薬市場2023-2030：薬剤クラス別（化学療法、免疫療法）、地域別（北米、アジア太平洋、中南米、ヨーロッパ）
  • 世界の胃がん市場2021年-2031年：疾患種類別（腺がん、リンパ腫、消化管間質腫瘍、カルチノイド腫瘍、その他）、治療種類別（免疫療法、標的療法、化学療法、放射線療法＆外科）、薬剤クラス別（PD-1/PD-L1阻害剤、HER2アンタゴニスト、VEGFR2アンタゴニスト、その他）、投与経路別（経口、注射剤）、流通チャネル別（病院薬局、専門薬局＆小売薬局、その他）
  • 世界の上咽頭がん治療市場2023-2031：治療種類別（放射線療法、化学療法、免疫療法、その他）、エンドユーザー別（病院、専門クリニック、その他）
  • 世界の上咽頭がん市場2022-2029：治療別（化学療法、免疫療法、放射線療法、その他）、エンドユーザー別、地域別
  • 胃がん治療のグローバル市場（～2030）：化学療法、免疫療法、放射線療法・手術
  • 世界の光線性角化症治療市場2023-2030：治療法別（外用、手術、光線力学的療法）、薬剤クラス別、エンドユーザー別、地域別
  • 世界の胸腺がん治療市場（~2033）：がん種類別（胸腺腫、胸腺がん）、治療法別（手術、放射線療法、化学療法、ホルモン療法、標的療法、免疫療法）、エンドユーザー別（病院＆クリニック、研究＆学術機関）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆